Duchenne UK is pleased to announce that TAMDMD, the Tamoxifen trial, led by Professor Dirk Fischer, has now been fully recruited for the main group of patients.

This means that in 12 months, these patients will have completed their 48 weeks of treatment and results of the trial can be expected in Spring 2021.

The Phase 1 Open Label Extension and Phase 2 Clinical Trial into Suvodirsen has been terminated on the basis of interim data.

We are very pleased to be able to share with you our first ever DMD Hub Impact Report. The report details all the incredible achievements and progress we have made to expand clinical trial capacity since 2014.

The Phase I/II Extension and the Phase I/III Clinical trial into Roche RO7239361 has been terminated, on the basis of interim data.

Duchenne UK announces funding of £193,487 for two new DMD Hub posts at Evelina Children’s Hospital in London, to help more patients with DMD in London and the South access clinical trials.

This will significantly expand trial capacity for Duchenne Muscular Dystrophy in the UK, particularly in the north west of England.

The charity's co-founder Alex Johnson -- recently awarded the Pride of Manchester -- said it was a huge boost to research in the region.

We are pleased to announce that Catabasis Pharmaceutical's PolarisDMD Phase 3 trial for edasalonexent is now recruiting in the UK at Bristol Royal Hospital for Children. Evelina London Children's Hospital, Great Ormond Street Hospital and Royal Manchester Children’s Hospital will begin recruitment soon.